-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PYmqxtzL1hrmzpzqvSwtga7FF3NqYetgsT/EL7nA40hk+v0keCINWlRt5JywBWu1 dS1U+HkE3jUo3apKLszE9A== 0000950133-97-001622.txt : 19970505 0000950133-97-001622.hdr.sgml : 19970505 ACCESSION NUMBER: 0000950133-97-001622 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19970502 SROS: NONE GROUP MEMBERS: BB BIOTECH AG GROUP MEMBERS: BIOTECH TARGET, S.A. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: XENOVA GROUP PLC CENTRAL INDEX KEY: 0000894770 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-45551 FILM NUMBER: 97594820 BUSINESS ADDRESS: STREET 1: 240 BATH ROAD SLOUGH SLI 4EF CITY: BERKSHIRE ENGLAND STATE: X0 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: DC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 2028351882 MAIL ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 SC 13D/A 1 BB BIOTECH SCHEDULE 13D/A RE: XENOVA GROUP PLC. 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* Under the Securities Exchange Act of 1934 XENOVA GROUP PLC ---------------- (Name of Issuer) ORDINARY SHARES OF 10p EACH --------------------------- (Title of Class of Securities) 984111104 --------- (CUSIP Number) DR. ANDREAS BREMER GRAFENAUWEG 4, 6301 ZUG CH/SWITZERLAND 011-41-41-724-5959 ------------------ (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) Copy to: Daniel L. Goelzer, Esq. Baker & McKenzie 815 Connecticut Avenue, N.W. Washington, D.C. 20006 MARCH 11, 1997 -------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d- 1(b)(3) or (4), check the following box [ ]. Check the following box if a fee is being paid with the statement [ ]. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. Page 1 of 5 Pages 2 The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 2 of 5 Pages 3 CUSIP No. 984111104 - ------------------------------------------------------------------------------- (1) Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person BB Biotech AG Biotech Target, S.A. - ------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member (a) [ ] of a Group (See Instructions) (b) [X] - ------------------------------------------------------------------------------- (3) SEC Use Only - ------------------------------------------------------------------------------- (4) Source of Funds (See Instructions) WC - ------------------------------------------------------------------------------- (5) Check Box if Disclosure of Legal Proceedings [ ] is Required Pursuant to Item 2(d) or 2(e) - ------------------------------------------------------------------------------- (6) Citizenship or Place of Organization BB Biotech AG -- Switzerland Biotech Target, S.A. -- Panama - ------------------------------------------------------------------------------- Number of Shares (7) Sole Voting Power: Beneficially Owned 0 by BB Biotech AG by Each Reporting --------------------------------- Person With (8) Shared Voting Power 100,000 (See Item 5) --------------------------------- (9) Sole Dispositive Power 0 by BB Biotech AG --------------------------------- (10) Shared Dispositive Power 100,000(See Item 5) --------------------------------- - ------------------------------------------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person 100,000 shares (See Item 5) - ------------------------------------------------------------------------------- (12) Check Box if the Aggregate Amount in Row (11) [ ] Excludes Certain Shares (See Instructions) - ------------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11) 0.79% - ------------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions) BB Biotech AG -- HC, CO Biotech Target, S.A. -- CO - ------------------------------------------------------------------------------- Page 3 of 5 Pages 4 SCHEDULE 13D This Amendment No. 1 reflects open market sales of 1,150,000 ordinary shares, 10p each ("Ordinary Shares"), of Xenova Group PLC ("Xenova") by Biotech Target S.A., a Panamanian corporation ("Biotech Target") and wholly owned subsidiary of BB Biotech AG, a Swiss corporation ("BB Biotech") during the period of March 6, 1997 through April 15, 1997. As of March 19, 1997, Biotech Target and BB Biotech ceased to have beneficial ownership of more than 5 percent of the outstanding ordinary shares of Xenova. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER ITEMS 5(a), (b), (c) AND (e) ARE AMENDED IN THEIR ENTIRETY TO READ AS FOLLOWS: (a) As of October 26, 1995, Biotech Target held 1,000,000 shares, or approximately 8.8 percent, of Xenova's outstanding ordinary shares. Since that time, Biotech Target has sold shares in the open market to reduce its holdings to 100,000 shares, or approximately 0.79 percent of the outstanding ordinary shares of Xenova, as reported in Xenova's Form 20-F for the period ending December 31, 1995. As a result of its ownership of Biotech Target, BB Biotech may be deemed to be the indirect beneficial owner of the Xenova ordinary shares held directly in the aggregate by Biotech Target as of April 11, 1997, which represents approximately 0.79 percent of the outstanding Xenova ordinary shares. No Xenova ordinary shares are directly owned by BB Biotech. To the best knowledge of BB Biotech and Biotech Target, no director or executive officer of BB Biotech or Biotech Target owns any Xenova ordinary shares. (b) The number of ordinary shares of Xenova to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or direct the disposition is set forth in the cover pages and such information is incorporated herein by reference. BB Biotech, through its ownership of Biotech Target, may be deemed to beneficially own the ordinary shares of Xenova within the meaning of Regulation 13D under the Exchange Act, and may be deemed to share with Biotech Target the power to vote or direct the vote of and the power to dispose of or direct the disposition of the aggregate 100,000 ordinary shares of Xenova directly held by Biotech Target. BB Biotech hereby expressly declares that the filing of this statement shall not be construed as an admission that it is, for purposes of Section 13(d) of the Exchange Act, the beneficial owner of the Xenova ordinary shares held by Biotech Target. (c) A summary of transactions in Xenova ordinary shares effected by Biotech Target during the past sixty days is attached Page 4 of 5 Pages 5 hereto as Exhibit A and such information is incorporated herein by reference. (e) As of March 19, 1997, BB Biotech and Biotech Target ceased to have beneficial ownership of more than 5 percent of Xenova's outstanding ordinary shares. SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BB BIOTECH AG Date: April 18, 1997 By:/s/ Hans-Joerg Graf* -------------------- Name: Hans-Joerg Graf Date: April 18, 1997 By:/s/ Dr. Victor Bischoff* ------------------------ Name: Dr. Victor Bischoff BIOTECH TARGET, S.A. Date: April 18, 1997 By:/s/ Dr. Andreas Bremer ---------------------- Name: Dr. Andreas Bremer Date: April 18, 1997 By:/s/ Dr. Anders Hove ------------------- Name: Dr. Anders Hove - ---------------- * See power of attorney, attached as an exhibit 99.E to the Schedule 13D relating to Biogen, Inc. filed with the Securities and Exchange Commission on June 2, 1994, which exhibit is incorporated by reference herein. Page 5 of 5 Pages 6 Exhibit A EXHIBIT A IS HEREBY AMENDED TO ADD THE FOLLOWING SUMMARY OF TRANSACTIONS IN XENOVA ORDINARY SHARES EFFECTED BY BIOTECH TARGET IN THE LAST 60 DAYS.
- -------------------------------------------------------------------------------------------- DATE TYPE OF TRANSACTION AND SALE PRICE BENEFICIALLY PERCENT OF NUMBER OF SHARES OF SHARES OWNED SHARES OUTSTANDING PER SHARE OWNED - -------------------------------------------------------------------------------------------- 3/6/97 Sale of 250,000 shares 5.04 1,000,000 7.96 - -------------------------------------------------------------------------------------------- 3/11/97 Sale of 125,000 shares 5.02 875,000 6.96 - -------------------------------------------------------------------------------------------- 3/13/97 Sale of 60,000 shares 5.12 815,000 6.49 - -------------------------------------------------------------------------------------------- 3/14/97 Sale of 50,000 shares 5.12 765,000 6.09 - -------------------------------------------------------------------------------------------- 3/17/97 Sale of 60,000 shares 5.02 705,000 5.61 - -------------------------------------------------------------------------------------------- 3/19/97 Sale of 100,000 shares 5.12 605,000 4.81 - -------------------------------------------------------------------------------------------- 3/21/97 Sale of 120,000 shares 5.12 485,000 3.86 - -------------------------------------------------------------------------------------------- 3/25/97 Sale of 40,000 shares 5.70 445,000 3.54 - -------------------------------------------------------------------------------------------- 3/26/97 Sale of 25,000 shares 5.62 420,000 3.34 - -------------------------------------------------------------------------------------------- 3/27/97 Sale of 60,000 shares 5.62 360,000 2.86 - -------------------------------------------------------------------------------------------- 3/31/97 Sale of 10,000 shares 5.50 350,000 2.79 - -------------------------------------------------------------------------------------------- 4/2/97 Sale of 150,000 shares 5.78 200,000 1.59 - -------------------------------------------------------------------------------------------- 4/7/97 Sale of 20,000 shares 5.75 180,000 1.43 - -------------------------------------------------------------------------------------------- 4/8/97 Sale of 10,000 shares 5.75 170,000 1.35 - -------------------------------------------------------------------------------------------- 4/11/97 Sale of 10,000 shares 5.75 160,000 1.27 - -------------------------------------------------------------------------------------------- 4/15/97 Sale of 60,000 shares 5.62 100,000 0.79 ============================================================================================
-----END PRIVACY-ENHANCED MESSAGE-----